Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

被引:216
作者
Ahmed, Asra [1 ]
Merrill, Samuel A. [2 ]
Alsawah, Fares [3 ]
Bockenstedt, Paula [1 ]
Campagnaro, Erica [1 ]
Devata, Sumana [1 ]
Gitlin, Scott D. [1 ]
Kaminski, Mark [1 ]
Cusick, Alice [1 ]
Phillips, Tycel [1 ]
Sood, Suman [1 ]
Talpaz, Moshe [1 ]
Quiery, Albert [1 ]
Boonstra, Philip S. [4 ,5 ]
Wilcox, Ryan A. [1 ]
机构
[1] Univ Michigan, Dept Internal Med, Div Hematol & Med Oncol, Rogel Canc Ctr, Ann Arbor, MI 48130 USA
[2] Johns Hopkins Univ Hosp, Dept Med, Div Hematol, Baltimore, MD 21287 USA
[3] Univ Michigan, Dept Internal Med, Div Hosp Med, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Ctr Canc Biostat, Ann Arbor, MI 48109 USA
关键词
INTERFERON-GAMMA; T-CELLS; MUTATIONS; ETOPOSIDE; EFFICACY; HLH;
D O I
10.1016/S2352-3026(19)30156-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Hemophagocytic lymphohistiocytosis is a cytokine-driven inflammatory syndrome that is associated with substantial morbidity and mortality. Overall survival in adult patients with secondary haemophagocytic lymphohistiocytosis remains suboptimal, and novel therapeutic strategies are needed. The phosphorylation-dependent activation of the Janus family kinases JAK1 and JAK2 are hallmarks of the final common pathway in this disease. We therefore aimed to determine the activity and safety of ruxolitinib, a JAK inhibitor, in adults with secondary haemophagocytic lymphohistiocytosis. Methods We performed an open-label, single-centre, pilot study of ruxolitinib in adults with secondary haemophagocytic lymphohistiocytosis at the University of Michigan Rogel Cancer Center (Ann Arbor, MI, USA). We included patients aged 18 years or more who fulfilled at least five of the eight HLH-2004 criteria for hemophagocytic lymphohistiocytosis. Discontinuation of corticosteroids was not required for enrolment in this study. Patients received oral ruxolitinib (15 mg twice a day) on a continuous 28-day cycle, or until disease progression or unacceptable toxicity. The primary endpoint was overall survival at 2 months from the first dose of ruxolitinib. Secondary endpoints included the assessment of adverse events, response (defined as the assessment of all quantifiable signs and laboratory abnormalities included in the diagnostic criteria for haemophagocytic lymphohistiocytosis), and pharmacodynamic biomarkers. Analyses were done in all treated patients with available data. This study is registered with ClinicalTrials. gov, number NCT02400463, and is still recruiting. Findings As of Feb 7, 2019, five patients had been enrolled. The first patient was enrolled in February, 2016. No deaths were recorded, with a median follow-up of 490 days (IQR 190-1075). 2-month overall survival was 100% (95% CI 57-100). Regarding response, resolution of symptoms (either partial or complete) and disease-associated laboratory abnormalities was observed in all five patients. Cytopenias improved in all patients within the first week of treatment, leading to relatively rapid transfusion independence, discontinuation of corticosteroids, and hospital discharge. A single serious adverse event (ie, grade 4 febrile neutropenia) was reported. One patient discontinued treatment because of grade 2 extremity pain and no treatment-related deaths were observed. Improvements in inflammatory markers (eg, ferritin, soluble IL-2 receptor) and T cells and monocytes activation (ie, decreased STAT1 phosphorylation) were observed following treatment. Interpretation These preliminary data suggest that ruxolitinib is active, well tolerated, and manageable in the outpatient setting in patients with secondary haemophagocytic lymphohistiocytosis. Given the paucity of effective, non-myelosuppressive therapies, these preliminary findings have important therapeutic implications for patients with haemophagocytic lymphohistiocytosis and other cytokine-release syndromes and warrant further investigation. Copyright (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页码:E630 / E637
页数:8
相关论文
共 30 条
[1]   INVOLVEMENT OF INTERFERON-GAMMA AND MACROPHAGE-COLONY-STIMULATING FACTOR IN PATHOGENESIS OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ADULTS [J].
AKASHI, K ;
HAYASHI, S ;
GONDO, H ;
MIZUNO, S ;
HARADA, M ;
TAMURA, K ;
YAMASAKI, K ;
SHIBUYA, T ;
UIKE, N ;
OKAMURA, T ;
MIYAMOTO, T ;
NIHO, Y .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (02) :243-250
[2]   Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study [J].
Bergsten, Elisabet ;
Horne, AnnaCarin ;
Arico, Maurizio ;
Astigarraga, Itziar ;
Egeler, R. Maarten ;
Filipovich, Alexandra H. ;
Ishii, Eiichi ;
Janka, Gritta ;
Ladisch, Stephan ;
Lehmberg, Kai ;
McClain, Kenneth L. ;
Minkov, Milen ;
Montgomery, Scott ;
Nanduri, Vasanta ;
Rosso, Diego ;
Henter, Jan-Inge .
BLOOD, 2017, 130 (25) :2728-2738
[3]   Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis [J].
Bracaglia, Claudia ;
de Graaf, Kathy ;
Marafon, Denise Pires ;
Guilhot, Florence ;
Ferlin, Walter ;
Prencipe, Giusi ;
Caiello, Ivan ;
Davi, Sergio ;
Schulert, Grant ;
Ravelli, Angelo ;
Grom, Alexei A. ;
de Min, Cristina ;
De Benedetti, Fabrizio .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) :166-172
[4]   Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis [J].
Broglie, Larisa ;
Pommert, Lauren ;
Rao, Sridhar ;
Thakar, Monica ;
Phelan, Rachel ;
Margolis, David ;
Talano, Julie .
BLOOD ADVANCES, 2017, 1 (19) :1533-1536
[5]   STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5 [J].
Cetica, Valentina ;
Santoro, Alessandra ;
Gilmour, Kimberly C. ;
Sieni, Elena ;
Beutel, Karin ;
Pende, Daniela ;
Marcenaro, Stefania ;
Koch, Florian ;
Grieve, Samantha ;
Wheeler, Rachel ;
Zhao, Fang ;
zur Stadt, Udo ;
Griffiths, Gillian M. ;
Arico, Maurizio .
JOURNAL OF MEDICAL GENETICS, 2010, 47 (09) :595-600
[6]   Hemophagocytic Lymphohistiocytosis: Advances in Pathophysiology, Diagnosis, and Treatment [J].
Chandrakasan, Shanmuganathan ;
Filipovich, Alexandra H. .
JOURNAL OF PEDIATRICS, 2013, 163 (05) :1253-1259
[7]   Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis [J].
Das, Rupali ;
Guan, Peng ;
Sprague, Leslee ;
Verbist, Katherine ;
Tedrick, Paige ;
An, Qi Angel ;
Cheng, Cheng ;
Kurachi, Makoto ;
Levine, Ross ;
Wherry, E. John ;
Canna, Scott W. ;
Behrens, Edward M. ;
Nichols, Kim E. .
BLOOD, 2016, 127 (13) :1666-1675
[8]   Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations [J].
Forbes, Lisa R. ;
Vogel, Tiphanie P. ;
Cooper, Megan A. ;
Castro-Wagner, Johana ;
Schussler, Edith ;
Weinacht, Katja G. ;
Plant, Ashley S. ;
Su, Helen C. ;
Allenspach, Eric J. ;
Slatter, Mary ;
Abinun, Mario ;
Lilic, Desa ;
Cunningham-Rundles, Charlotte ;
Eckstein, Olive ;
Olbrich, Peter ;
Guillerman, R. Paul ;
Patel, Niraj C. ;
Demirdag, Yesim Y. ;
Zerbe, Christa ;
Freeman, Alexandra F. ;
Holland, Steven M. ;
Szabolcs, Paul ;
Gennery, Andrew ;
Torgerson, Troy R. ;
Milner, Joshua D. ;
Leiding, Jennifer W. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 142 (05) :1665-1669
[9]   Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation [J].
Henter, JI ;
Samuelsson-Horne, A ;
Aricò, M ;
Egeler, RM ;
Elinder, G ;
Filipovich, AH ;
Gadner, H ;
Imashuku, S ;
Komp, D ;
Ladisch, S ;
Webb, D ;
Janka, G .
BLOOD, 2002, 100 (07) :2367-2373
[10]   Etoposide Selectively Ablates Activated T Cells To Control the Immunoregulatory Disorder Hemophagocytic Lymphohistiocytosis [J].
Johnson, Theodore S. ;
Terrell, Catherine E. ;
Millen, Scott H. ;
Katz, Jonathan D. ;
Hildeman, David A. ;
Jordan, Michael B. .
JOURNAL OF IMMUNOLOGY, 2014, 192 (01) :84-91